混合方法研究以支持使用新的淋巴瘤特异性患者报告的症状措施,这些措施来自EORTC项目库
Jessica T Markowitz1, Flora Mazerolle2, Teya Lovell1
1Modus Outcomes, A Division of THREAD Research, Cambridge, MA, USA.
Journal of patient-reported outcomes
|January 22, 2024
概括
这项研究开发并验证了慢性淋巴细胞白血病 (CLL) /小淋巴细胞淋巴瘤 (SLL) 和地幔细胞淋巴瘤 (MCL) 患者报告的症状措施. 这些新的EORTC项目库工具显示出在临床试验中评估患者症状的前景.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 患者报告的结果
背景情况:
- 对于慢性淋巴细胞白血病 (CLL) /小淋巴细胞淋巴瘤 (SLL) 或地幔细胞淋巴瘤 (MCL) 没有经过验证的患者报告的症状措施.
- 评估患者报告的症状及其影响对于管理这些罕见的血液恶性瘤至关重要.
- 这项研究旨在确定和评估CLL/SLL和MCL患者的相关症状评估项目.
结论:
- 定性和初步的定量数据支持EORTC项目库评估CLL/SLL和MCL症状和影响.
- 这些项目组是临床试验中测量患者报告结果的有希望的候选人.
- 需要对更大的样本大小进行进一步验证,以确定可用于临床试验的强大的心理测量特性.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...